Circulating serum microRNA biomarkers and methods

A method, comprising the steps of:

• obtaining a sample of a kind selected from the group consisting of whole blood, plasma and serum from a human patient;
• determining a differential level of at least two miRNAs selected from the group consisting of SEQ ID NOS:
• 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 22, 24, 25, 27, 28, 31, 30, 32, 33, 37, 38, 40, 42, 43, 44, 46, 47, 48, 49, 50, 51, 55, 56, 57, 58, 59, 60, 62, 63, 64, 67, 68, 71, 72, 74, 75, 77, 78, 80, 81, 85 and 86 within said sample compared to a differential level in a sample of the same kind from a healthy control;
• correlating differential levels of at least 1.2 fold above that of the healthy control for said miRNAs to a disease state of Parkinson's disease in said human patient;
• and
• administering treatment for Parkinson's disease to said human patient, wherein
• said treatment comprises administering L-dopa, peripheral decarboxylase inhibitor, dopamine agonist, catechol-O-methyltransferase inhibitor, amantadine or a monoamine oxidase B inhibitor to said human patient.

A method, comprising the steps of:

• obtaining a sample of a kind selected from the group consisting of whole blood, plasma and serum from a human patient;
• determining a differential level of at least two miRNAs selected from the group consisting of SEQ ID NOS:
• 4, 17, 18, 19, 20, 21, 23, 26, 29, 34, 35, 36, 39, 45, 52, 53, 54, 61, 65, 66, 69, 70, 73, 76, 79, 82, 83 and 84 within said sample compared to a differential level in a sample of the same kind from a healthy control;
• correlating differential levels of at least 1.2 fold above that of the healthy control for said miRNAs to a disease state of Parkinson's disease in said human patient;
• and
• administering treatment for Parkinson's disease to said human patient, wherein
• said treatment comprises administering L-dopa, peripheral decarboxylase inhibitor, dopamine agonist, catechol-O-methyltransferase inhibitor, amantadine or a monoamine oxidase B inhibitor to said human patient.

A method, comprising the steps of:

• obtaining a sample of a kind selected from the group consisting of whole blood, plasma and serum from a human patient;
• determining a differential level of at least one miRNA selected from the group consisting of SEQ ID NOS:
• 15, 22, 24, 25, 52, 54, 55 and 77 within said sample compared to a differential level in a sample of the same kind from a healthy control;
• correlating differential levels of at least 1.2 fold above that of the healthy control for said miRNAs to a disease state of Parkinson's disease in said human patient;
• and
• administering treatment for Parkinson's disease to said human patient, wherein
• said treatment comprises administering L-dopa, peripheral decarboxylase inhibitor, dopamine agonist, catechol-O-methyltransferase inhibitor, amantadine or a monoamine oxidase B inhibitor to said human patient.